Company: BSTZ
Filing Date: 2025-02-25
Form Type: SC TO-I/A
Source: 0001193125-25-034130
Chunk: 1

Company: BlackRock Science & Technology Term Trust
Filing Date: 2025-02-25
Form: SC TO-I/A
Chunk 1
---
”), in connection with an offer by the Fund (the “Offer”) to repurchase 2.5% of its issued and outstanding common shares of beneficial interest, par value
$0.001 per share (the “Shares”), in exchange for cash at a price equal to 98% of the net asset value (“NAV”) per Share determined as of the close of the regular trading session of the New York Stock Exchange, the principal market
on which the Shares are traded, on the next day the NAV is calculated after the Offer expires, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated January 23, 2025 (the “Original Offer to Purchase”),
the Supplement No. 1 to the Original Offer to Purchase, dated January 23, 2025 (the “Supplement No. 1” and together with the Original Offer to Purchase, the “Offer to Purchase”), and in the related Letter of
Transmittal, copies of which were previously filed as Exhibits (a)(1)(i), (a)(1)(ii) and (a)(1)(iii), respectively, to the Schedule TO.

This Amendment
No. 1 is being filed to update Item 12 of the Schedule TO to include a press release announcing the preliminary results of the Offer, which expired on February 24, 2025, at 5:00 p.m. Eastern time. A copy of the press release is attached
hereto as Exhibit (a)(5)(ii).

Except as specifically provided herein, the information contained in the Schedule TO, the Offer to Purchase and the Letter
of Transmittal remains unchanged, and this Amendment No. 1 does not modify any of the information previously reported in the Schedule TO, the Offer to Purchase or the Letter of Transmittal.

Item 1 through Item 9 and Item 11

The information
set forth in the Offer to Purchase and the related Letter of Transmittal is incorporated by reference into this Amendment No. 1 in answer to Item 1 through Item 9 and Item 11 of the Schedule TO.

Item 10. Financial Statements

(a)
The audited annual financial statements of the Fund dated December31, 2023 and the schedule of investments of the Fund dated December31, 2023, both filed with the SEC on EDGAR on Form N-CSRon March6, 2024, are incorporated by reference. The unaudited semi-annual financial statements of the